Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: CSO
Company: Tavotek Biotherapeutics
个人简介:
Dr. Mark Chiu has been in the pharmaceutical development industry for over 25 years and has rich experience in the R&D management of multinational pharmaceutical enterprises. He was the supervisor of multiple key R&D departments in Johnson & Johnson and Abbott, responsible for leading the early R&D of several blockbusting pharmaceutical products, for example Darzalex(Daratumumab)、Tremfya (Gesulkumab)、Remicade (Infliximab), Rybruvent (amivantamab), Teclistamab, Ciltacabtagene autoleucel, etc. before the founding of Tavotek Pharmaceuticals. Within only three years, he developed nine new molecular entities (NME) for Johnson & Johnson. He graduated with a BA Biophysics from the University of California Berkeley and Ph.D Biochemistry from the University of Illinois Urbana-Champaign.   He was a post-doctoral fellow working with two Nobel winners, was in study sections in European and United States Scientific Committees.
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: Founder and CEO
Company: Tavotek Biotherapeutics
个人简介:
Shengfeng founded Bio-Thera in 2003, and has served since that time as Chief Executive Officer and as a member of our Board of Directors. Prior to founding Bio-Thera, Shengfeng was a founder and founding Chief Scientific Officer of Abmaxis, Inc., California (acquired by Merck). Prior to co-founding Abmaxis, he was employed at Cor Therapeutics, (merged with Millennium). Dr. Li received his Ph.D. in Microbiology from the University of Georgia in 1991, and afterwards, he worked as a postdoctoral scientist and later as a Donoghue Foundation fellow at Yale, where he identified several Raf kinase signaling regulatory molecules such as RKIP and 14-3-3 family of proteins. Dr. Li is an author on multiple publications in peer reviewed journals such as Nature, EMBO, Gene & Dev, and PNAS. He is an inventor on over 50 patents in the areas of target identification, drug discovery, antibody engineering, and product development.
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: CEO
Company: Shanghai Genbase Biotechnology Co. Ltd
个人简介:
Dr. Jijun Yuan is co-founder and chief executive officer of Shanghai Genbase Biotechnology Co. Ltd, which was established in 2015 to focus on developing new therapeutic drugs, including cell therapies, gene therapies and therapeutic antibodies. Prior to that, Dr. Jijun Yuan spent six years at Shanghai Hengrui Pharmaceutical Co. as the associate director in charge of the biological division. He has been involved in more than 30 drug discovery programs, including oncology, diabetes and cardiovascular therapeutic drugs.  Dr. Jijun Yuan holds a PhD degree in molecular biology from Ohio State University and worked as postdoctoral researcher at University of California Los Angeles.
发布时间: 2021 - 08 - 18
点击次数: 0
Positions: Head of Business Development & Licensing, China and APAC
Company: Bayer Healthcare
个人简介:
Betty Huang is currently the Head of Business Development and Licensing for China/APAC region at Bayer Healthcare Company. She is experienced in business development with comprehensive finance, investment and healthcare industry knowledge, and led Bayer China/APAC BD&L team to accomplish multiple transactions with both global and domestic partners. Highlighted recent partnership projects include collaboration with an Chinese innovative biotech pioneering in Diabetes, Italian pharmaceutical company entering into respiratory area, and high-end US device technology company.Before Joining Bayer, Betty worked at KPMG and Deloitte as audit and M&A transaction services professionals, during which she gained a lot of experience in deal execution and due diligence.Betty graduated from University of York with master degree in Finance and Investment, and holds Australia CPA.